The table below shows Relay Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$235.46M
-$249.11M
-$300.32M
-$229.49M
-$74.41M
-$102.49M
Capital expenditure
$410.00K
$2.02M
$4.13M
$9.06M
$3.47M
$1.93M
Investing cash flow
$192.80M
-$41.08M
$257.63M
-$188.75M
-$479.51M
$81.67M
Dividends paid
-
-
-
-
-
RLAY operating cash flow (10-K history)
Relay Therapeutics, Inc. reported operating cash flow of -$235.46M for fiscal year 2025. That is up 5.5% from -$249.11M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$66.13M (FY 2019) to -$235.46M. Figures come from the company's audited annual reports as filed with the SEC.
